A Study to Assess the Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), or Chronic Lymphocytic Leukemia (CLL)
M22-716
Phase 1 other active
Quick answer
A Study to Assess the Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), or Chronic Lymphocytic Leukemia (CLL) for Follicular lymphoma (FL), Chronic lymphocytic leukemia (CLL), Diffuse large b-cell lymphoma (DLBCL), B-cell malignancies is a Phase 1 program (other) at AbbVie Deutschland GmbH & Co. KG with 1 ClinicalTrials.gov record(s).
Program details
- Company
- AbbVie Deutschland GmbH & Co. KG
- Indication
- Follicular lymphoma (FL), Chronic lymphocytic leukemia (CLL), Diffuse large b-cell lymphoma (DLBCL), B-cell malignancies
- Phase
- Phase 1
- Modality
- other
- Status
- active